# US 2020/0347058 A1 · S1pr2 antagonists and uses therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0347058 A1
- Document ID: US20200347058A1
- Status: Published application
- Kind: A1
- Application number: 16/930,039
- Filed: 2020-07-15
- Published: 2020-11-05
- Earliest claimed: 2015-06-01
- Assignees: Dalhousie University
- Applicants: Dalhousie University
- Inventors: Christopher McMaster; Gordon Simms
- Web page: https://patentgrep.com/patent/US20200347058A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- C07C 229/24: having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
- C07C 317/48: the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07F 9/3808: {Acyclic saturated acids which can have further substituents on alkyl}
- C07J 31/006: {not covered by C07J31/003}
- C07F 9/091: {with hydroxyalkyl compounds with further substituents on alkyl}
- C07F 9/65583: {each of the hetero rings containing nitrogen as ring hetero atom}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C07J: STEROIDS (seco-steroids C07C)

## Abstract

Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) through the administration of a therapeutically effective amount of a sphingosine-1-phosphate receptor type 2 (S1PR2) antagonist. Also provided herein are compounds which contain bioisosteric replacements of the urea group of JTE-013 and analogs thereof, and their use in treating retinopathies and diseases characterized by insufficient angiogenesis.

## Claims

### Claim 1

A method for treating ocular diseases that are caused by a primary defect in retinal vascularization followed by secondary aberrant neovascularization that can result in retina detachment, the method comprising the administration of a pharmaceutically effective amount of a compound of formula IX, or any pharmaceutically-acceptable salt thereof:
wherein
R1 is C1-C12 alkyl;
R2, R3, and R4 are each independently hydrogen, halogen, C1-C6 alkyl, C1-C4 alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4 alkylamino, C3-C7 cycloalkyl or C3-C7 cycloalkyloxy;
R3 and R4 can be positioned at h, i or j, but not simultaneously at the same position;
each instance of R5 is independently selected from hydrogen, halogen, C1-C6 alkyl, C1-C4 alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4 alkylamino, C3-C7 cycloalkyl, and C3-C7 cycloalkyloxy;
n is 0, 1, 2, 3 or 4;
X is NRa, CH2, or —C(═O)—, wherein each instance of Ra is independently selected from hydrogen and C1-C3 alkyl;
Y1 and Y2 are each independently selected from NRa, CH2, and O; and
Z is any geometric isomer of a group selected from one of the following:

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound is a compound of formula V:

### Claim 3 (depends on 2)

The method of claim 2, wherein
R1 is CH3; and
R2 is CH3.

### Claim 4 (depends on 3)

The method of claim 3, wherein
R3 is H; and
R4 is C1-C6 alkyl.

### Claim 5 (depends on 4)

The method of claim 4, wherein
R4 is CH(CH3)2.

### Claim 6 (depends on 5)

The method of claim 5, wherein
R5 is halogen.

### Claim 7 (depends on 6)

The method of claim 6, wherein
R5 is Cl; and
n is 2.

### Claim 8 (depends on 2)

The method of claim 2, wherein
R1 is CH3;
R2 is CH3;
R3 is H;
R4 is CH(CH3)2;
R5 is Cl; and
n is 2.

### Claim 9 (depends on 1)

The method of claim 1, wherein the ocular diseases include familial exudative vitreoretinopathy.

### Claim 10 (depends on 1)

The method of claim 1, wherein the compound of formula IX is a S1PR2 antagonist.

### Claim 11

A compound for inhibiting SIPR2 receptors to treat an eye condition comprising the following formula IX, or any pharmaceutically-acceptable salt thereof:
wherein
R1 is C1-C12 alkyl;
R2, R3, and R4 are each independently hydrogen, halogen, C1-C6 alkyl, C1-C4 alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4 alkylamino, C3-C7 cycloalkyl or C3-C7 cycloalkyloxy;
R3 and R4 can be positioned at h, i or j, but not simultaneously at the same position;
each instance of R5 is independently selected from hydrogen, halogen, C1-C6 alkyl, C1-C4 alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4 alkylamino, C3-C7 cycloalkyl, and C3-C7 cycloalkyloxy;
n is 0, 1, 2, 3 or 4;
X is NRa, CH2, or —C(═O)—, wherein each instance of Ra is independently selected from hydrogen and C1-C3 alkyl;
Y1 and Y2 are each independently selected from NRa, CH2, and O; and
Z is any geometric isomer of a group selected from one of the following:

### Claim 12 (depends on 11)

The compound of claim 11, wherein the compound is a compound of formula V:
and wherein
R1 is CH3; and
R2 is CH3.

### Claim 13 (depends on 12)

The compound of claim 12, wherein
R3 is H; and
R4 is C1-C6 alkyl.

### Claim 14 (depends on 13)

The compound of claim 13, wherein
R5 is Cl; and
n is 2.

### Claim 15 (depends on 11)

The compound of claim 11, wherein
R1 is CH3;
R2 is CH3;
R3 is H;
R4 is CH(CH3)2;
R5 is Cl; and
n is 2.

### Claim 16 (depends on 11)

The compound of claim 11, wherein the eye condition includes familial exudative vitreoretinopathy.

### Claim 17 (depends on 11)

The compound of claim 11, wherein the eye condition includes an inability to normally vascularize the eye.

### Claim 18 (depends on 11)

The compound of claim 11, wherein the eye condition includes secondary aberrant neovascularization.

### Claim 19

A method for treating ocular diseases that are caused by a primary defect in retinal vascularization followed by secondary aberrant neovascularization that can result in retina detachment comprising the administration of a pharmaceutically effective amount of a compound selected from the following, or any pharmaceutically-acceptable salt thereof:

### Claim 20 (depends on 19)

The method of claim 19, wherein the ocular diseases include familial exudative vitreoretinopathy.

### Claim 21 (depends on 19)

The method of claim 19, wherein the compound is a S1PR2 antagonist.

### Claim 22

A method for treating an eye condition, the method comprising the administration of a pharmaceutically effective amount of a compound of formula IV, or any pharmaceutically-acceptable salt thereof:
wherein
Ar is aromatic heterocycle;
W is NRa—, O, or —CH2—, wherein Ra is hydrogen or C1-C3 alkyl;
Z is —C(═O)—, —C(═S)—, O, —CH2—, ═N—, or ═CH—;
Y is —NRa—, —C(═O)—, —N═, —CH═, ═N—, or ═CH—; and
X is —NRa—, —N═, —CH═, or —CH2—;
R1 is C1-C12 alkyl;
R2, R3, and R4 are each independently hydrogen, halogen, C1-C6 alkyl, C1-C4alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4alkylamino, C3-C7cycloalkyl, or C3-C7cycloalkyloxy;
R3 and R4 can be positioned at h, i, or j, but not simultaneously at the same position; and
X2 is N or —CRb— wherein Rb is hydrogen, halogen, C1-C6 alkyl, C1-C4alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4alkylamino, C3-C7cycloalkyl, or C3-C7cycloalkyloxy.

### Claim 23 (depends on 22)

The method of claim 22, wherein the eye condition includes familial exudative vitreoretinopathy.

### Claim 24 (depends on 22)

The method of claim 22, wherein the compound of formula IV is a S1PR2 antagonist.

### Claim 25 (depends on 22)

The method of claim 22, wherein the eye condition includes consequent aberrant neovascularization.

### Claim 26 (depends on 22)

The method of claim 22, wherein the eye condition includes consequent loss of retinal integrity or retinal detachment.

### Claim 27 (depends on 22)

The method of claim 22, wherein the eye condition includes a primary defect in retinal vascularization followed by secondary aberrant neovascularization.

### Claim 28 (depends on 22)

The method of claim 22, wherein the compound of formula IV is effective in normalizing vascularization of the retina in subjects that are at risk of hypovascularization or avascularization during retinal development followed by aberrant ocular neovascularization that may compromise retinal integrity and function.

### Claim 29

A method for treating an eye condition, the method comprising the administration of a pharmaceutically effective amount of at least one compound of formula I to formula X, or any pharmaceutically-acceptable salt thereof.

### Claim 30 (depends on 29)

The method of claim 29, wherein the at least one compound is a S1PR2 antagonist.

### Claim 31 (depends on 29)

The method of claim 29, wherein the eye condition includes familial exudative vitreoretinopathy.

### Claim 32 (depends on 29)

The method of claim 29, wherein the eye condition includes an inability to normally vascularize the eye.

### Claim 33 (depends on 29)

The method of claim 29, wherein the eye condition includes secondary aberrant neovascularization.

### Claim 34 (depends on 29)

The method of claim 29, wherein the eye condition includes restoration of retinal vasculature patterning.

### Claim 35 (depends on 29)

The method of claim 29, wherein the eye condition includes prevention of familial exudative vitreoretinopathy retinal vascularization defects.

### Claim 36 (depends on 29)

The method of claim 29, wherein the eye condition includes consequent aberrant neovascularization.

### Claim 37 (depends on 29)

The method of claim 29, wherein the eye condition includes consequent loss of retinal integrity or retinal detachment.

### Claim 38 (depends on 29)

The method of claim 29, wherein the eye condition includes a primary defect in retinal vascularization followed by secondary aberrant neovascularization.

### Claim 39 (depends on 29)

The method of claim 29, wherein the at least one compound is effective in normalizing vascularization of the retina in subjects that at risk of hypovascularization or avascularization during retinal development followed by aberrant ocular neovascularization that may compromise retinal integrity and function.

### Claim 40

A method for treating an eye condition, the method comprising the administration of a pharmaceutically effective amount of at least one compound of PubChem ID 3382778, PubChem ID 44317142, PubChem ID 54736865, PubChem ID 3866342, PubChem ID 46891770, PubChem ID 51624406, PubChem ID 9578291, PubChem ID 9864156, PubChem ID 365015, PubChem ID 28094480, PubChem ID 40592676, PubChem ID 10883396, PubChem ID 342302, PubChem ID 59623845, PubChem ID 54734912, PubChem ID 18390590, PubChem ID 56923928, PubChem ID 51508548, PubChem ID 28960354, PubChem ID 51624683, or PubChem ID 27993, or any pharmaceutically-acceptable salt thereof.

### Claim 41 (depends on 40)

The method of claim 40, wherein the at least one compound is a S1PR2 antagonist.

### Claim 42 (depends on 40)

The method of claim 40, wherein the eye condition includes familial exudative vitreoretinopathy.

### Claim 43 (depends on 40)

The method of claim 40, wherein the eye condition includes an inability to normally vascularize the eye.

### Claim 44 (depends on 40)

The method of claim 40, wherein the eye condition includes secondary aberrant neovascularization.

### Claim 45 (depends on 40)

The method of claim 40, wherein the eye condition includes restoration of retinal vasculature patterning.

### Claim 46 (depends on 40)

The method of claim 40, wherein the eye condition includes prevention of familial exudative vitreoretinopathy retinal vascularization defects.

### Claim 47 (depends on 40)

The method of claim 40, wherein the eye condition includes consequent loss of retinal integrity or retinal detachment.

### Claim 48 (depends on 40)

The method of claim 40, wherein the eye condition includes a primary defect in retinal vascularization followed by secondary aberrant neovascularization.

### Claim 49 (depends on 40)

The method of claim 40, wherein the at least one compound is effective in normalizing vascularization of the retina in subjects that at risk of hypovascularization or avascularization during retinal development followed by aberrant ocular neovascularization that may compromise retinal integrity and function.

### Claim 50

A method for treating an eye condition, the method comprising the administration of a pharmaceutically effective amount of at least one compound of formula I to formula X, or any pharmaceutically-acceptable salt thereof.

### Claim 51 (depends on 50)

The method of claim 50, wherein the at least one compound is a S1PR2 antagonist.

### Claim 52 (depends on 50)

The method of claim 50, wherein the eye condition includes familial exudative vitreoretinopathy.

### Claim 53 (depends on 50)

The method of claim 50, wherein the eye condition includes an inability to normally vascularize the eye

### Claim 54 (depends on 50)

The method of claim 50, wherein the eye condition includes secondary aberrant neovascularization.

### Claim 55 (depends on 50)

The method of claim 50, wherein the eye condition includes restoration of retinal vasculature patterning.

### Claim 56 (depends on 50)

The method of claim 50, wherein the eye condition includes prevention of familial exudative vitreoretinopathy retinal vascularization defects.

### Claim 57

A compound for inhibiting SIPR2 receptors to treat an eye condition comprising the following formula IX, or any pharmaceutically-acceptable salt thereof:
wherein
R1 is C1-C12 alkyl;
R2, R3, and R4 are each independently hydrogen, halogen, C1-C6 alkyl, C1-C4 alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4 alkylamino, C3-C7 cycloalkyl or C3-C7 cycloalkyloxy;
R3 and R4 can be positioned at h, i or j, but not simultaneously at the same position;
each instance of R5 is independently selected from hydrogen, halogen, C1-C6 alkyl, C1-C4 alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4 alkylamino, C3-C7 cycloalkyl, and C3-C7 cycloalkyloxy;
n is 0, 1, 2, 3 or 4;
X is NRa, CH2, or —C(═O)—, wherein each instance of Ra is independently selected from hydrogen and C1-C3 alkyl;
Y1 and Y2 are each independently selected from NRa, CH2, and O; and
Z is any geometric isomer of a group selected from one of the following:

### Claim 58 (depends on 57)

The compound of claim 57, selected from the group consisting of

### Claim 59 (depends on 57)

The compound of claim 57, wherein Z is not —C(═O)—.

### Claim 60

A compound of general formula (IX),
wherein
R1 is C1-C12 alkyl;
R2, R3, and R4 are each independently hydrogen, halogen, C1-C6 alkyl, C1-C4 alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4 alkylamino, C3-C7 cycloalkyl or C3-C7 cycloalkyloxy;
R3 and R4 can be positioned at h, i or j, but not simultaneously at the same position;
each instance of R5 is independently selected from hydrogen, halogen, C1-C6 alkyl, C1-C4 alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4 alkylamino, C3-C7 cycloalkyl, and C3-C7 cycloalkyloxy;
n is 0, 1, 2, 3 or 4;
X is NRa, CH2, or —C(═O)—, wherein each instance of Ra is independently selected from hydrogen and C1-C3 alkyl;
Y1 and Y2 are each independently selected from NRa, CH2, and O; and
Z is any geometric isomer of a group selected from one of the following:
or any pharmaceutically acceptable salt thereof.

### Claim 61 (depends on 60)

A pharmaceutical composition comprising the compound of claim 60 and a pharmaceutically acceptable carrier.

### Claim 62 (depends on 60)

A method of treating a retinopathy, comprising administering the compound of claim 60 to a subject in need thereof.

### Claim 63 (depends on 62)

The method of claim 62, wherein the retinopathy is selected from the group consisting of diabetic retinopathy, macular degeneration, hypertensive retinopathy, radiation retinopathy, solar retinopathy, retinopathy of prematurity (ROP), Norrie disease (ND), familial exudative vitreoretinopathy (FEVR), Coats' disease, sickle cell retinopathy, and retinitis pigmentosa.

### Claim 64 (depends on 63)

The method of claim 63, wherein the retinopathy is FEVR.

### Claim 65 (depends on 60)

A method of treating a disease characterized by insufficient angiogenesis, comprising administering the compound of claim 60 to a subject in need thereof.

### Claim 66 (depends on 65)

The method of claim 65, wherein the disease is selected from the group consisting of atherosclerosis, hypertension, diabetes, restenosis, pre-eclampsia, menorrhagia, neonatal respiratory distress, pulmonary fibrosis, nephropathy, osteoporosis, amyotrophic lateral sclerosis, stroke, and Alzheimer's disease.

### Claim 67

A compound of general formula (X),
wherein,
R1 is C1-C12 alkyl;
R2, R3, and R4 are each independently hydrogen, halogen, C1-C6 alkyl, C1-C4 alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4 alkylamino, C3-C7 cycloalkyl or C3-C7 cycloalkyloxy;
R3 and R4 can be positioned at h, i, or j, but not simultaneously at the same position;
each instance of R5 is independently selected from hydrogen, halogen, C1-C6 alkyl, C1-C4 alkoxy, C1-C6 perhaloalkyl, C1-C4 perhaloalkoxy, amino, mono- or di-C1-C4 alkylamino, C3-C7 cycloalkyl, and C3-C7 cycloalkyloxy;
n is 0, 1, 2, 3 or 4;
X and Y are each independently selected from NRa, O, and CH2, wherein each instance of Ra is independently selected from hydrogen and C1-C3 alkyl;
and Z is any geometric isomer of a group selected from one of the following:
or any pharmaceutically acceptable salt thereof.

### Claim 68 (depends on 67)

The compound of claim 67, selected from the group consisting of:

### Claim 69 (depends on 67)

A pharmaceutical composition comprising the compound of claim 67 and a pharmaceutically acceptable carrier.

### Claim 70 (depends on 67)

A method of treating a retinopathy, comprising administering the compound of claim 67 to a subject in need thereof.

### Claim 71 (depends on 67)

The method of claim 67, wherein the retinopathy is selected from the group consisting of diabetic retinopathy, macular degeneration, hypertensive retinopathy, radiation retinopathy, solar retinopathy, retinopathy of prematurity (ROP), Norrie disease (ND), familial exudative vitreoretinopathy (FEVR), Coats' disease, sickle cell retinopathy, and retinitis pigmentosa.

### Claim 72 (depends on 71)

The method of claim 71, wherein the retinopathy is FEVR.

### Claim 73 (depends on 67)

A method of treating a disease characterized by insufficient angiogenesis, comprising administering the compound of claim 67 to a subject in need thereof.

### Claim 74 (depends on 73)

The method of claim 73, wherein the disease is selected from the group consisting of atherosclerosis, hypertension, diabetes, restenosis, pre-eclampsia, menorrhagia, neonatal respiratory distress, pulmonary fibrosis, nephropathy, osteoporosis, amyotrophic lateral sclerosis, stroke, and Alzheimer's disease.
